FDA approves Grifols’ Xembify to treat primary immunodeficiencies
According to the company, Xembify (immune globulin subcutaneous, human- klhw) is a 20% immune globulin solution for subcutaneous injection indicated to treat primary humoral immunodeficiency (PI) in patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.